title: [Soluble syndecan-1 levels in different plasma cell dyscrasias].
abstract: BACKGROUND
  Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias.
  
  
  METHODS
  The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit.
  
  
  RESULTS
  Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders.
  
  
  CONCLUSIONS
  These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.
authors.affiliation: Országos Gyógyintézeti Központ, Haematológiai-Haemosztazeológiai Osztály, Budapest. janosijudit@hotmail.com
authors.forename: Judit
authors.initials: J
authors.lastname: Jánosi
authors.forename: Anna
authors.initials: A
authors.lastname: Sebestyén
authors.forename: Gábor
authors.initials: G
authors.lastname: Mikala
authors.forename: Mónika
authors.initials: M
authors.lastname: Petö
authors.forename: János
authors.initials: J
authors.lastname: Jákó
authors.forename: Gyula
authors.initials: G
authors.lastname: Domján
authors.forename: Júlia
authors.initials: J
authors.lastname: Németh
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Kis
authors.forename: László
authors.initials: L
authors.lastname: Kopper
authors.forename: István
authors.initials: I
authors.lastname: Vályi-Nagy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D010265:Paraproteinemias / Q000097:blood*; D010954:Plasmacytoma / Q000097:blood*; D011509:Proteoglycans / Q000097:blood*; D012995:Solubility; D053668:Syndecan-1; D053667:Syndecans
chemical_list: D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans